Avior Wealth Management LLC Buys 581 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Avior Wealth Management LLC increased its stake in Regeneron Pharmaceuticals by 66.0%, owning a total of 1,461 shares worth approximately $767,000 after acquiring an additional 581 shares.
• Regeneron Pharmaceuticals recently announced a quarterly dividend of $0.88 per share, with a dividend yield of 0.6% and a payout ratio of 8.87%.
• Analyst ratings for Regeneron are positive, with a consensus rating of "Moderate Buy" and an average target price of $817.67, indicating strong investor confidence.

Avior Wealth Management LLC boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 66.0% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,461 shares of the biopharmaceutical company's stock after buying an additional 581 shares during the quarter. Avior Wealth Management LLC's holdings in Regeneron Pharmaceuticals were worth $767,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. Kingswood Wealth Advisors LLC lifted its holdings in Regeneron Pharmaceuticals by 1.8% during the first quarter. Kingswood Wealth Advisors LLC now owns 1,084 shares of the biopharmaceutical company's stock valued at $681,000 after purchasing an additional 19 shares during the last quarter. Creative Financial Designs Inc. ADV lifted its holdings in Regeneron Pharmaceuticals by 9.5% during the first quarter. Creative Financial Designs Inc. ADV now owns 220 shares of the biopharmaceutical company's stock valued at $139,000 after purchasing an additional 19 shares during the last quarter. Private Trust Co. NA lifted its holdings in Regeneron Pharmaceuticals by 13.1% during the first quarter. Private Trust Co. NA now owns 164 shares of the biopharmaceutical company's stock valued at $104,000 after purchasing an additional 19 shares during the last quarter. Proficio Capital Partners LLC lifted its holdings in Regeneron Pharmaceuticals by 6.2% during the first quarter. Proficio Capital Partners LLC now owns 327 shares of the biopharmaceutical company's stock valued at $207,000 after purchasing an additional 19 shares during the last quarter. Finally, Cove Private Wealth LLC lifted its holdings in Regeneron Pharmaceuticals by 4.5% during the first quarter. Cove Private Wealth LLC now owns 460 shares of the biopharmaceutical company's stock valued at $292,000 after purchasing an additional 20 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. BMO Capital Markets upped their price objective on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an "outperform" rating in a research report on Monday, August 4th. Redburn Atlantic upgraded shares of Regeneron Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, August 14th. Morgan Stanley restated an "overweight" rating and issued a $761.00 price objective (up from $754.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Jefferies Financial Group upped their price objective on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a "buy" rating in a research report on Wednesday, August 27th. Finally, Citigroup restated a "buy" rating and issued a $650.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Three analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $817.67.

Regeneron Pharmaceuticals Stock Down 0.6%

Shares of NASDAQ REGN opened at $560.75 on Tuesday. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,061.60. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. The firm's 50 day simple moving average is $570.09 and its two-hundred day simple moving average is $568.76. The stock has a market capitalization of $59.43 billion, a P/E ratio of 14.13, a PEG ratio of 1.80 and a beta of 0.35.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. The business had revenue of $3.68 billion for the quarter, compared to analysts' expectations of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business's quarterly revenue was up 3.6% on a year-over-year basis. During the same period last year, the business earned $11.56 earnings per share. As a group, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend was Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio is 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.